The current “gold standard” test for esophageal cancer is endoscopic imaging and confirmed by biopsy. There are several barriers to endoscopy as a clinical tool to monitor patients at high risk for esophageal cancer, including cost, highly invested personnel, and invasive nature. encroachment of the procedure. The article below highlights new insights into the development and clinical validation of respiratory and circulatory biomarkers of esophageal cancer.